Every material Form 8-K Starling Oncology, Inc. has filed with the SEC since August 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Starling Oncology reported third-quarter 2026 revenue of $169.8 million, up 24.3% from a year earlier, and a net loss of $15.7 million, narrower than $16.5 million a year earlier. The company narrowed its full-year 2026 Adjusted EBITDA guidance and lowered the top end of its revenue and free cash flow ranges, so the outlook is mixed for shareholders.
Q3 2026 revenue was $169.8 million, up from $136.6 million; net loss was $15.7 million versus $16.5 million, or $(0.13) per share versus $(0.14).
Adjusted EBITDA, a non-GAAP measure, was $3.4 million versus $(3.5) million a year earlier.
2026 revenue guidance is now $650 million to $660 million, down from $650 million to $670 million; free cash flow guidance is now $5 million to $10 million, down from $5 million to $15 million.
2026 Adjusted EBITDA guidance narrowed to $4 million to $6 million from $2 million to $7 million; gross profit guidance is now $107 million to $110 million, up at the low end from $105 million.
Starling Oncology director Brad Hively told the company on September 1, 2026 that he will not stand for re-election to the Board at the 2027 annual meeting. He remains a director until that meeting but immediately stepped down as Vice Chairman and from the Compliance Committee and other Board committees. The company says the decision did not stem from any disagreement over its operations, policies or practices.
Brad Hively will not stand for re-election to the Board at the 2027 annual meeting of stockholders.
Hively remains a director until the 2027 annual meeting, per the filing.
Effective immediately, Hively no longer serves as Vice Chairman or on the Compliance Committee or other Board committees.
The filing states the decision was not the result of any disagreement with the company.
On August 20, 2026, subsidiary Starling Oncology Management, LLC entered a revolving credit agreement with Gemino Healthcare Finance, LLC (d/b/a SLR Healthcare ABL) for up to $25 million. The filing says the company is not required or expected to borrow the full amount, and that it is intended to provide financial flexibility if needed. Shareholders should note the facility is secured by substantially all of the subsidiary's assets and carries a covenant on loan turn days.
Facility of up to $25 million, dated August 20, 2026, maturing August 20, 2029
Interest at Term SOFR plus 3.95%, with Term SOFR floored at 2.00% per annum
$4,750,000 outstanding as of August 21, 2026 (the filing text reads "$4,750,000 million")
Secured by a first-priority security interest in substantially all of the subsidiary's collateral; covenant limits Maximum Loan Turn Days to 35 on a rolling three-month basis
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Starling Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →